抗体
试剂盒
多肽
探针
蛋白
组织芯片
产品中心
Product Center
Research Grade Glofitamab
All
TD-HY257146_1.jpg
TD-HY257146_2.jpg
- Catalog： TD-HY257146
- Clonality： mAb
- Application： Research Grade Biosimilar
- Synonyms： Bispecific, CD20-TCB (2:1), RG-6026, CAS: 2229047-91-8
-
规格：
1mg
-
价格：
¥询价
定制服务咨询
Research Grade Glofitamab
| Catalog No. | TD-HY257146 |
|---|---|
| Description | Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab is an investigational, T-cell bispecific antibody with a distinctive design that features 2 Fab arms for binding CD20 on B cells, along with 1 Fab arm for binding CD3 on T cells. The CD3 binding arm is fused directly to one of the CD20-binding arms in a head-to-tail fashion via a short flexible linker. |
| Species reactivity | Human |
| Applications | Research Grade Biosimilar |
| Host species | Humanized |
| Isotype | IgG1-kappa-lambda |
| Expression system | Mammalian Cells |
| Species | Human |
| Clonality | Monoclonal |
| Target | B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P11836 & P07766 |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names | Bispecific, CD20-TCB (2:1), RG-6026, CAS: 2229047-91-8 |
| Background | Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL). |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|
|
Detects CD3E in indirect ELISAs. |
|
|
SDS-PAGE for Research Grade Glofitamab. |